BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma Meeting Abstract
| Authors: | Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; Davids, M. S.; Chang, A. E.; Oliveira, J. M.; Lu, Y.; Leow, C. Ch.; Roeker, L. E.; Woyach, J. A. |
| Abstract Title: | BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS7583 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS7583 -- Meeting was also available virtually -- Source: Cinahl |
